



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/632,711	
			Filing Date	August 1, 2003	
			First Named Inventor	Carson, Dennis A.	
			Art Unit	1614	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	023070-124010US

U.S. PATENT DOCUMENTS+						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
M6	AA	US-3,097,137		07-09-1963	Beer et al.	
	AB	US 3,205,220		09-07-1965	Svoboda et al.	
	AC	US-3,880,995		04-29-1975	Jones	
	AD	US-3,991,078		11-09-1976	Witkowski et al.	
	AE	US-4,136,175		01-23-1979	Rideout	
	AF	US-4,138,547		02-06-1979	Christensen et al.	
	AG	US-4,451,848		05-29-1984	Parsons et al.	
	AH	US-4,680,285		07-14-1987	Robins	
	AI	US-4,727,069		02-23-1988	Nelson et al.	
	AJ	US-4,753,935		06-28-1988	Nelson et al.	
	AK	US-4,786,637		11-22-1988	Allison et al.	
	AL	US-4,996,237		02-26-1991	Pettit et al.	
	AM	US-5,405,837		04-11-1995	Weber	
	AN	US-5,472,947		12-05-1995	Saida et al.	
	AO	US-5,492,897		02-20-1996	Krenitsky et al.	
	AP	US-5,561,122		10-01-1996	Kamp et al.	
	AQ	US-5,571,510		11-05-1996	Nobori et al.	
	AR	US-5,747,472		05-05-1998	Krenitsky et al.	
	AS	US-5,821,238		10-13-1998	Krenitsky et al.	
	AT	US-5,840,505		11-24-1998	Carrera et al.	
	AU	US-5,942,393		08-24-1999	Nobori et al.	
	AV	US 6,162,810		12-19-2000	Carson et al.	
	AW	US-6,210,917		04-03-2000	Carson et al.	
	AX	US-6,214,571		04-10-2001	Carrera et al.	
	AY	US-6,306,874		10-23-2001	Fraley et al.	
	AZ	US-6,395,763 B1		05-28-2002	Stamos et al.	
	BA	US-2002/0082678		06-27-2002	Sirhan et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
Mb 	BB	WO	98/40381	A1	09-17-1998			<input type="checkbox"/>
	BC	WO	99/55663	A1	11-04-1999			<input type="checkbox"/>
	BD	WO	00/10600	A2	03-02-2000			<input type="checkbox"/>
	BE	WO	00/26197	A1	05-11-2000			<input type="checkbox"/>
	BF	WO	00/33876	A1	06-15-2000			<input type="checkbox"/>
	BG	WO	00/35865	A2	06-22-2000			<input type="checkbox"/>
	BH	WO	00/40269	A2	07-13-2000			<input type="checkbox"/>

Examiner
SignatureDate
Considered

10/21/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/632,711	
			Filing Date	August 1, 2003	
			First Named Inventor	Carson, Dennis A.	
			Art Unit	1614	
			Examiner Name	Not Yet Assigned	
Sheet		of		Attorney Docket Number	023070-124010US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
M6	BI	WO	01/00622	A1	01-04-2001			<input type="checkbox"/>
I	BJ	WO	01/87324	A1	11-22-2001			<input type="checkbox"/>
	BK	WO	04/12746	A3	02-12-2004			<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
M6	BL	ALLISON, A.C. et al.; "Immunological Observations on Patients with Lesch-Nyhan Syndrome, and on the role of De-Novo Purine Transformation"; 1975, <u>The Lancet</u> , pp. 1179-1183.	
	BM	ALLISON, A.C. et al.; "The role of <i>de novo</i> purine sythesis in lymphocyte transformation"; 1977, <u>Ciba Found. Symp.</u> , Vol. 48, pp. 207-224.	
	BN	BEDDOWS, Clifford G. et al.; "Synthesis and reactions of 2-(5-amino-4-carbamoylimidazol-1-yl)-2-deoxy-D-glucose, an analog of a naturally occurring imidazole nucleoside"; 1975, <u>Chemical Abstracts Service</u> , 2 page abstract.	
	BO	CATAPANO, Carlo V. et al.; "GTP Depletion Induced by IMP Dehydrogenase Inhibitors Blocks RNA-Primed DNA Synthesis"; 1995, <u>Molecular Pharmacology</u> , Vol. 47, No. 5, pp. 948-955.	
	BP	CARDUCCI, Michael A. et al.; "Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics"; 2002, <u>Journal of Clinical Oncology</u> , Vol. 20, No. 8, pp. 2171-2180.	
	BQ	CHABNER, B.A. et al.; "Antineoplastic Agents"; 1996, <u>Goodman and Gilman's the Pharmacological Basis of Therapeutics</u> , Vol. 9, pp. 1243-1247.	
	BR	de BONO, Johann S. et al.; "The ErbB receptor family: a therapeutic target for cancer"; 2002, <u>Trends in Molecular Medicine</u> , Vol. 8, No. 4, pp. S19-S26.	
	BS	DHANASEKARAN, N. et al.; "G Protein-Coupled Receptor Systems Involved in Cell Growth and Oncogenesis"; 1995, <u>Endocrine Reviews</u> , Vol. 16, No. 3, pp. 259-270.	
	BT	DOWNS, Stephen M. et al.; "Induction of Mouse Oocyte Maturation in Vivo by Perturbants of Purine Metabolism"; 1987, <u>Biology of Reproduction</u> , Vol. 36, pp. 431-437.	
	BU	DRUKER, Brian J.; "STI571 (Gleevec™) as a paradigm for cancer therapy"; 2002, <u>Trends in Molecular Medicine</u> , Vol. 8, No. 4, pp. S14-S18.	
	BV	ERLICHMAN, Charles; "Hormonal Therapies in Cancer"; 1997, <u>Principles and Practice in Oncology</u> , Vol. 5, pp. 395-405.	
I	BW	FLANAGAN, Colleen A. et al.; "Advances in understanding gonadotrophin-releasing hormone receptor structure and ligand interactions"; 1997, <u>Reviews of Reproduction</u> , Vol. 2, pp. 113-120.	

Examiner Signature	<i>Michael Gaffes</i>	Date Considered	6/21/05
--------------------	-----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/632,711	
			Filing Date	August 1, 2003	
			First Named Inventor	Carson, Dennis A.	
			Art Unit	1614	
			Examiner Name	Not Yet Assigned	
Sheet		of		Attorney Docket Number	023070-124010US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MB	BX	FOREMAN, Kimberly E.; "Kaposi's sarcoma: the role of HHV-8 and HIV-1 in pathogenesis"; 2001, <u>Expert Reviews</u> , pp. 1-17.	
	BY	FUKUI, Masaru et al.; "New Antitumor Imidazole Derivative, 5-Carbamoyl-1 H-imidazol-4-yl Piperonylate, as an Inhibitor of Purine Synthesis and Its Activation by Adenine Phosphoribosyltransferase"; 1982, <u>Cancer Research</u> , Vol. 42, pp. 1098-1102.	
	BZ	GANDHI, Varsha.; "Novel Inhibitors of DNA Replication"; 1999, <u>Hematology</u> , pp. 463-469.	
	CA	GILCHRIST, Annette et al.; "Antagonists of the Receptor-G Protein Interface Block G _i -Coupled Signal Transduction"; 1998, <u>The Journal of Biological Chemistry</u> , Vol. 273, No. 24, pp. 14912-14919.	
	CB	GLASSOCK, Richard J.; "The treatment of Iga nephropathy: status at the end of the millennium"; 1999, <u>J. Nephrol.</u> , Vol. 12, pp. 288-296.	
	CC	GREGORY, R.K. et al.; "Vinorelbine - a clinical review"; 2000, <u>British Journal of Cancer</u> , Vol. 82, No. 12, pp. 1907-1913.	
	CD	GUPTA, R.S. et al.; "Cross resistance pattern towards anticancer drugs of a human carcinoma multidrug-resistant cell line"; 1988, <u>Br. J. Cancer</u> , Vol. 58, pp. 441-447.	
	CE	HEALY, Dennis P.; "[28] Genetic Analysis of G Protein-Coupled Receptor Genes, 2002, <u>Methods in Enzymology</u> , Vol. 353, pp. 448-459.	
	CF	HOESSEL, Ralph et al.; "Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases"; 1999, <u>Nature Cell Biology</u> , Vol. 1, pp. 60-67.	
	CG	HUA, Xuequn Helen et al.; "Biochemical Genetic Analysis of Indanocene Resistance In Human Leukemia"; 2001, <u>Cancer Research</u> , Vol. 61, pp. 7248-7254.	
	CH	INSEL, P.; "Analgesic-Antipyretic and Antiinflammatory Agents and Drugs Employed in the Treatment of Gout"; 1996, <u>Goodman and Gilman's the Pharmacological Basis of Therapeutics</u> , Vol. 9, pp. 647-649.	
	CI	ISHIKAWA, Hiroaki; "Mizoribine and Mycophenolate Mofetil"; 1999, <u>Current Medicinal Chemistry</u> , Vol. 6, pp. 575-597.	
	CJ	JEMAL, Ahmedin et al.; "Cancer Statistics 2002"; 2002, <u>CA Cancer J. Clin.</u> , Vol. 52, pp. 23-47.	
	CK	KARAGIRL, Nobuya et al.; "Synthesis of Pyrazofurin and Its Analogues"; 1984, <u>J. Chem. Soc. Perkin Trans. 1</u> , pp. 553-560.	
	CL	KISLIUK, Roy L.; "Synergistic interactions among antifolates"; 2000, <u>Pharmacology & Therapeutics</u> , Vol. 85, pp. 183-190.	
	CM	KISOR, David F. et al.; "Pharmacokinetics of Nelarabine and 9-Beta-d-Arabinofuranosyl Guanine in Pediatric and Adult Patients During a Phase I Study of Nelarabine for the Treatment of Refractory Hematologic Malignancies"; 2000, <u>Journal of Clinical Oncology</u> , Vol. 18, No. 5, pp. 995-1003.	

Examiner Signature	<i>Michael Jaffee</i>	Date Considered	10/21/05
-----------------------	-----------------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/632,711	
			Filing Date	August 1, 2003	
			First Named Inventor	Carson, Dennis A.	
			Art Unit	1614	
			Examiner Name	Not Yet Assigned	
Sheet		of		Attorney Docket Number	02307O-124010US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MB	CN	LEONI, Lorenzo M. et al.; "Indanocine, a Microtubule-Binding Indanone and a Selective Inducer of Apoptosis in Multidrug-Resistant Cancer Cells"; 2000, <u>Journal of the National Cancer Institute</u> , Vol. 92, No. 3, pp. 217-224.	
	CO	MACKENZIE, Grahame et al.; "Purines, pyrimidines, and imidazoles. Part 48. Some acyclic D-arabinose imidazole and purine nucleosides"; 1977, <u>Chemical Abstracts Service</u> , 2 page abstract.	
	CP	MACKENZIE, Grahame et al.; "Synthesis of a novel acyclic D-arabinose nucleoside"; 1975, <u>Chemical Abstracts Service</u> , 2 page abstract.	
	CQ	MAJUMDAR, Alokes et al.; "IL-3 and Ribavirin Induce Differentiation and Growth Suppression During Long-Term Treatment of a Megakaryocytic Leukemia Cell Line"; 1995, <u>Journal of Cellular Physiology</u> , Vol. 165, pp. 530-537.	
	CR	MIZUNO, Kimio, et al.; "Studies on Breddlinin. I: Isolation, Characterization and Biological Properties"; 1974, <u>The Journal of Antibiotics</u> , Vol. 27, No. 10, pp. 775-782.	
	CS	MORRIS, Randall E.; "Mechanisms of action of new immunosuppressive drugs"; 1996, <u>Kidney International</u> , Vol. 49, Supple. 53, pp. S26-S38.	
	CT	NAGY, Attila et al.; "Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin"; 1998, <u>PNAS</u> , Vol. 95, pp. 1794-1799.	
	CU	OLAH, Edith et al.; "Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells"; 1988, <u>PNAS</u> , Vol. 85, pp. 6533-6537.	
	CV	OLAH, Edith et al.; "Molecular Mechanisms in the Antiproliferative Action of Taxol and tiazofurin"; 1996, <u>Anticancer Research</u> , Vol. 16, pp. 2469-2478.	
	CW	PRAJDA, Noemi et al.; "Sequential Impact of Tiazofurin and Ribavirin on the Enzymic Program of the Bone Marrow"; 1993, <u>Cancer Research</u> , Vol. 53, pp. 5982-5986.	
	CX	PRENZEL, Norbert et al.; "EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF"; 1999, <u>Nature</u> , Vol. 402, pp. 884-888.	
	CY	Roy, K.K. et al.; "Early Development of Cyclin Dependent Kinase Modulators"; 2001, <u>Current Pharmaceutical Design</u> , Vol. 7, pp. 1669-1687.	
	CZ	SEASHOLTZ, Tammy M. et al.; "Rho as a Mediator of G Protein-Coupled Receptor Signaling"; 1999, <u>The American Society for Pharmacology and Experimental Therapeutics</u> , Vol. 55, pp. 949-956.	
	DA	SEIDENFELD, Jerome et al.; "Androgenic Regulation of 5'-Deoxy-5'-Methylthioadenosine Concentrations and Methylthioadenosine Phosphorylase Activity in Relation to Polyamine Metabolism of Rat Prostate"; 1980, <u>Biochemical and Biophysical Research Communications</u> , Vol. 95, No. 4, pp. 1861-1868.	
	DB	SEUWEN, Klaus et al.; "G Protein-Controlled Signal Transduction Pathways and the Regulation of Cell Proliferation"; 1992, <u>Advances in Cancer Research</u> , Vol. 58, pp. 75-94.	
	DC	SHAW, Leslie M. et al.; "Mycophenolate Mofetil: A Report of the Consensus Panel"; 1995, <u>Therapeutic Drug Monitoring</u> , Vol. 17, pp. 690-699.	

Examiner Signature	<i>Michael Gaffney</i>	Date Considered	10/21/05
--------------------	------------------------	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/632,711		
		Filing Date	August 1, 2003		
		First Named Inventor	Carson, Dennis A.		
		Art Unit	1614		
		Examiner Name	Not Yet Assigned		
Sheet		of		Attorney Docket Number	023070-124010US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MB	DD	SHAWYER, Laura K. et al.; "Smart Drugs: Tyrosine kinase inhibitors in cancer therapy"; 2002, <u>Cancer Cell</u> , Vol. 1, pp. 117-132.	
	DE	SLICHENMYER, William J. et al.; "Anticancer Therapy Targeting the ErbB Family of Receptor Tyrosine Kinases"; 2001, <u>Seminars in Oncology</u> , Vol. 28, No. 5, Suppl. 16, pp. 67-79.	
	DF	SODHI, Akrit et al.; "The Kaposi's Sarcoma-associated Herpes Virus G Protein-coupled Receptor Up-Regulates Vascular Endothelial Growth Factor Expression and Secretion through Mitogen-activated Protein Kinase and p38 Pathways Acting on Hypoxia-inducible Factor 1 α "; 2000, <u>Cancer Research</u> , Vol. 60, pp. 4873-4880.	
	DG	SOLLINGER, H.W. et al.; "Mycophenolate Mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients"; 1995, <u>Transplantation</u> , Vol. 60, No. 3, pp. 225-232.	
	DH	STRANGE, Philip G.; "Agonist binding to G-protein coupled receptors"; 2000, <u>British Journal of Pharmacology</u> , Vol. 129, pp. 820-821.	
	DI	THOMSON, A.W. et al.; "Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures"; 1993, <u>Transplant Immunology</u> , Vol. 1, pp. 146-150.	
	DJ	TRICOT, Guido et al.; "Tiazofurin: Biological Effects and Clinical Uses"; 1990, <u>International Journal of Cell Cloning</u> , Vol. 8, pp. 161-170.	
	DK	VALLEE, Sebastien et al.; "Ribavirin-induced resistance to heat shock, inhibition of the Ras-Raf-1 pathway and arrest in G ₁ "; 2000, <u>European Journal of Pharmacology</u> , Vol. 4, pp. 49-62.	
	DL	WEBER, George; "Advances in Enzyme Regulation"; 1989, <u>Proceedings of the International Conference on Critical Issues in Chemotherapy</u> , Vol. 29, pp. 75-95.	
	DM	WEBER, George; "Purine and Pyrimidine Metabolism in Man VII"; 1991, <u>Advances in Experimental Medicine and Biology</u> , Vol. 309B, pp. 287-292.	
	DN	WEBER, George et al.; "Tiazofurin Down-Regulates Expression of c-Ki-ras Oncogene in a Leukemic Patient"; 1991, <u>Cancer Communications</u> , Vol. 3, No. 3, pp. 61-66.	
	DO	WOOLAM, Gerald L.; "Cancer Statistics 2000: A Benchmark for the New Century"; 2000, <u>CA Cancer J. Clin.</u> , Vol. 50, No. 7, pp. 33.	
	DP	YALOWITX, Joel A. et al.; "Molecular Targets of Guanine Nucleotides in Differentiation, Proliferation and Apoptosis"; 2000, <u>Anticancer Research</u> , Vol. 20, pp. 2329-2338.	
	DQ	ZOU, Ruiming et al.; "Synthetic Approaches to the Guanosine and Xanthosine Analogues 5-Amino-3- β -D-ribofuranosylpyrazolo [3,4-3][1,3]oxazin-7-one and 3- β -D-Ribofuranosylpyrazolo[3,4-e][1,3]oxazine-5,7-dione and Studies of Their Antitumor Potential"; 1991, <u>J. Med. Chem.</u> , Vol. 34, pp. 1951-1959.	

Examiner Signature	<i>Michael Shapiro</i>	Date Considered	10/21/05
--------------------	------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.